IRD Opus Genetics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1228627 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-45.9%
TTM net income YoY-100.4%
TTM EPS YoY20.4%
Revenue 3-yr CAGR-48.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-777.7%
Net margin-1,726.7%
FCF margin—
EBITDA margin-776.9%
Returns
ROE-615.6%
ROA-208.0%
ROIC (approx.)—
Asset turnover0.12x
Leverage & solvency
Liabilities / assets59.7%
Debt / equity0.93x
Current ratio9.65x
Interest coverage-217.47x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-134.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.14M | $755,000 | $2.16M | $3.87M | $3.08M | $2.88M | $4.37M | $4.30M |
| R&D expense | $14.49M | $11.21M | $10.58M | $10.43M | $6.41M | $6.02M | $7.95M | $7.03M |
| SG&A expense | $5.89M | $6.03M | $5.94M | $4.89M | $4.98M | $5.77M | $6.35M | $7.30M |
| Operating income | -$19.25M | -$16.48M | -$14.36M | -$11.45M | -$8.31M | -$8.91M | -$9.93M | -$38.03M |
| Interest expense | $79,000 | $74,000 | $69,000 | $61,000 | $68,000 | $0 | $0 | $0 |
| Pretax income | -$46.49M | -$8.10M | -$65.53M | -$16.52M | -$17.45M | -$7.42M | -$8.19M | -$35.13M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$46.49M | -$8.10M | -$65.53M | -$16.52M | -$17.45M | -$7.42M | -$8.19M | -$35.13M |
| EBITDA | -$19.23M | -$16.47M | -$14.35M | -$11.44M | -$8.30M | -$8.89M | -$9.92M | -$38.02M |
| EPS (basic) | -0.46 | -0.08 | -0.75 | — | -0.25 | -0.12 | -0.24 | — |
| EPS (diluted) | -0.46 | -0.14 | -0.75 | — | -0.25 | -0.12 | -0.24 | — |
| Weighted avg. shares (diluted) | 101.84M | 111.38M | 86.89M | — | 70.64M | 63.38M | 33.88M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $88.97M | $88.81M | $59.96M | $45.09M | $30.82M | $32.43M | $41.79M | $30.32M |
| Short-term investments | — | — | — | $0 | $0 | $0 | $1,000 | $2,000 |
| Receivables | $1.00M | $1.04M | $1.73M | $2.00M | $2.92M | $3.40M | $3.08M | $3.56M |
| Current assets | $94.86M | $92.70M | $66.60M | $50.04M | $35.91M | $38.44M | $47.93M | $36.61M |
| PP&E, net | $339,000 | $172,000 | $186,000 | $199,000 | $212,000 | $226,000 | $239,000 | $252,000 |
| Total assets | $95.30M | $92.97M | $66.79M | $50.24M | $36.12M | $38.66M | $48.17M | $36.86M |
| Current liabilities | $9.83M | $7.61M | $9.34M | $7.78M | $29.09M | $20.19M | $24.25M | $11.29M |
| Long-term debt | $35.65M | $35.28M | $1.20M | $1.13M | $1.07M | $1.00M | — | $0 |
| Total debt | $35.65M | $35.28M | $1.20M | $1.13M | $1.07M | $1.00M | — | $0 |
| Total liabilities | $56.86M | $105.95M | $87.89M | $34.90M | $30.16M | $21.19M | $24.25M | $11.29M |
| Shareholders' equity | $38.43M | -$12.99M | -$45.84M | $15.35M | $5.97M | $17.47M | $5.07M | $6.72M |
| Net debt | -$53.32M | -$53.53M | -$58.76M | -$43.96M | -$29.75M | -$31.43M | — | -$30.32M |
| Shares outstanding | 95.80M | 82.65M | 71.40M | 69.89M | 64.54M | 59.91M | 45.48M | 31.57M |
| Cash flow statement | ||||||||
| Operating cash flow | -$14.04M | -$11.95M | -$12.73M | -$9.83M | -$6.16M | -$10.27M | -$8.99M | -$7.44M |
| Investing cash flow | -$189,000 | $0 | $0 | $0 | $0 | $0 | $0 | $1.21M |
| Financing cash flow | $14.39M | $40.90M | $27.59M | $24.11M | $4.54M | $906,000 | $20.46M | -$83,000 |
| Depreciation & amortization | $22,000 | $14,000 | $13,000 | $13,000 | $13,000 | $14,000 | $13,000 | $10,000 |
| Stock-based compensation | $1.59M | $1.41M | $1.46M | $774,000 | $816,000 | $896,000 | $913,000 | $795,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.